Phase III Clinical Pharmacology Study of Tolvaptan

[1]  Tadashi Okada,et al.  Pharmacokinetics, Pharmacodynamics and Safety of Tolvaptan, A Novel, Oral, Selective Nonpeptide AVP V2-receptor Antagonist: Results of Single- and Multiple-Dose Studies in Healthy Japanese Male Volunteers , 2011, Cardiovascular Drugs and Therapy.

[2]  M. Hori,et al.  Effects of Tolvaptan on Volume Overload in Japanese Patients with Heart Failure: Results of a Phase II, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study , 2011, Cardiovascular Drugs and Therapy.

[3]  C. O'connor,et al.  Loop Diuretics in Acute Decompensated Heart Failure: Necessary? Evil? A Necessary Evil? , 2009, Circulation. Heart failure.

[4]  K. Swedberg,et al.  Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. , 2007, JAMA.

[5]  K. Swedberg,et al.  Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. , 2007, JAMA.

[6]  T. Berl,et al.  Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. , 2006, The New England journal of medicine.

[7]  J. Ouyang,et al.  Vasopressin-2-receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failure. , 2006, American journal of physiology. Renal physiology.

[8]  L. Neyses,et al.  Diuretic usage in heart failure: a continuing conundrum in 2005. , 2005, European heart journal.

[9]  M. Gheorghiade,et al.  Vasopressin V2-Receptor Blockade With Tolvaptan in Patients With Chronic Heart Failure: Results From a Double-Blind, Randomized Trial , 2003, Circulation.

[10]  L. Stevenson,et al.  Clinical assessment identifies hemodynamic profiles that predict outcomes in patients admitted with heart failure. , 2003, Journal of the American College of Cardiology.

[11]  I. Anand,et al.  Diuretics in chronic heart failure — benefits andhazards , 2001 .

[12]  M. Domanski,et al.  Diuretics and risk of arrhythmic death in patients with left ventricular dysfunction. , 1999, Circulation.

[13]  T Yamashita,et al.  OPC-41061, a highly potent human vasopressin V2-receptor antagonist: pharmacological profile and aquaretic effect by single and multiple oral dosing in rats. , 1998, The Journal of pharmacology and experimental therapeutics.

[14]  P. Poole‐Wilson,et al.  Untreated heart failure: clinical and neuroendocrine effects of introducing diuretics. , 1987, British heart journal.

[15]  J. Ornato,et al.  ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult—Summary Article , 2005 .

[16]  Y. Yamamura,et al.  Effects of the V(2)-receptor antagonist OPC-41061 and the loop diuretic furosemide alone and in combination in rats. , 2000, The Journal of pharmacology and experimental therapeutics.

[17]  J. Ockene.  Baseline rest electrocardiographic abnormalities, antihypertensive treatment, and mortality in the Multiple Risk Factor Intervention Trial. Multiple Risk Factor Intervention Trial Research Group. , 1985, The American journal of cardiology.